9310 A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer.
Vergote, I Dean, Emma J Lassen, U De Bono, J Drew, Y Machiels, J Nielsen, D Arkenau, H Forster, M Jones, R
Vergote, I
Dean, Emma J
Lassen, U
De Bono, J
Drew, Y
Machiels, J
Nielsen, D
Arkenau, H
Forster, M
Jones, R
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
9310 A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. 2017, 28(suppl_5): Ann Oncol